囊泡单胺转运体
帕金森病
壳核
内科学
单胺类
内分泌学
尾状核
囊泡单胺转运体2
黑质
结合势
正电子发射断层摄影术
心理学
化学
医学
神经科学
多巴胺
多巴胺能
单胺类神经递质
多巴胺转运体
疾病
血清素
受体
作者
Nicolaas I. Bohnen,Roger L Albm,Robert A. Koeppe,K. Wernette,Michael R. Kilbourn,Satoshi Minoshima,Kirk A. Frey
标识
DOI:10.1038/sj.jcbfm.9600276
摘要
The type-2 vesicular monoamine transporter (VMAT2) might serve as an objective biomarker of Parkinson disease (PD) severity. Thirty-one subjects with early-stage PD and 75 normal subjects underwent continuous intravenous infusion of (+)-[ 11 C]dihydrotetrabenazine (DTBZ) and positron emission tomography (PET) imaging to estimate the striatal VMAT2 binding site density with equilibrium tracer modeling. Parkinson disease patients were evaluated clinically in the practically defined ‘off’ state with the Unified Parkinson Disease Rating Scale (UPDRS), the Hoehn and Yahr Scale (HY), and the Schwab and England Activities of Daily Living Scale (SE). In normal subjects there was age-related decline in striatal DTBZ binding, approximating 0.5% per year. In PD subjects, specific DTBZ binding was reduced in the caudate nucleus (CD; −44%), anterior putamen (−68%), and posterior putamen (PP; −77%). The PP-to-CD ratio of binding was reduced significantly in PD subjects. Dihydrotetrabenazine binding was also reduced by approximately 50% in the PD substantia nigra. Striatal binding reductions correlated significantly with PD duration and SE scores, but not with HY stage or with UPDRS motor subscale (UPDRS III ) scores. Striatal and midbrain DTBZ binding was asymmetric in PD subjects, with greatest reductions contralateral to the most clinically affected limbs. There was significant correlation between asymmetry of DTBZ binding and clinical asymmetry measured with the UPDRS III . In HY stage 1 and 1.5 subjects ( n = 16), PP DTBZ binding contralateral to the clinically unaffected body side was reduced by 73%, indicating substantial preclinical nigrostriatal pathology in PD. We conclude that (+)-[ 11 C]DTBZ-PET imaging displays many properties necessary of a PD biomarker.
科研通智能强力驱动
Strongly Powered by AbleSci AI